Optimus Medical Testing

BEFORE GETTING STARTED!

▪In order to participate in any of Optimus Medical Testing’s programs you MUST be HIPAA certified.

▪This includes any agents in the field as well as any administrators who will be dealing with any Patient information

▪You can get certified here https://courseforhipaa.com/terms-and-conditions

▪Once certified, please send a copy of the certificate to Onboarding@optimuscommercegroup.com

▪No agents will be activated without a HIPAA certificate. There can be no exceptions.

Welcome to Optimus Medical Testing!

Optimus Medical Testing was founded with a singular goal. To help educate patients about their health to allow them to make informed decisions about their treatment plans with their doctors.

Each and every one of us is different. This can make it quite difficult for doctors to development an effective treatment plan for their patients. As technology improves so to do the tools available to doctors that allow them to specifically tailor treatment plans to each and every patient!

OPT helps to provide these new tools to patients so they can live a healthier, happier lifestyle!

HEREDITARY CANCER SCREENING (CGx)

▪Did you know?

▪In 2018, an estimated 1,735,350 new cases of cancer will be diagnosed in the United States and 609,640 people will die from the disease.

▪The most common cancers (listed in descending order according to estimated new cases in 2018) are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer.

▪The number of new cases of cancer (cancer incidence) is 439.2 per 100,000 men and women per year (based on 2011–2015 cases).

▪The number of cancer deaths (cancer mortality) is 163.5 per 100,000 men and women per year (based on 2011–2015 deaths).

▪Cancer mortality is higher among men than women (196.8 per 100,000 men and 139.6 per 100,000 women). When comparing groups based on race/ethnicity and sex, cancer mortality is highest in African American men (239.9 per 100,000) and lowest in Asian/Pacific Islander women (88.3 per 100,000).

▪In 2016, there were an estimated 15.5 million cancer survivors in the United States. The number of cancer survivors is expected to increase to 20.3 million by 2026.

▪Approximately 38.4% of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2013–2015 data).

▪In 2017, an estimated 15,270 children and adolescents ages 0 to 19 were diagnosed with cancer and 1,790 died of the disease.

▪Estimated national expenditures for cancer care in the United States in 2017 were $147.3 billion. In future years, costs are likely to increase as the population ages and cancer prevalence increases. Costs are also likely to increase as new, and often more expensive, treatments are adopted as standards of care.

https://www.cancer.gov/about-cancer/understanding/statistics

What is Hereditary Cancer Screening?

Molecular testing looks for specific inherited changes (mutations) in a person’s genetic make-up. Genetic mutations may have multiple different effects on a patient’s health. Mutations that are harmful may increase a person’s chance, or risk, of developing a disease such as a cancer. Inherited mutations are thought to play a role in more than 10% of all cancers. These particular conditions are considered hereditary and appropriate genetic testing may be used to determine an individual’s risk which may allow them to take precautionary measures.

Some people inherit mutation(s) in the germline, allowing for the mutations to be passes on from their parents and to their children. There are two classes of cellular genes: oncogenes and tumor suppressor genes. Often, multiple genetic mutations in a single individual are responsible for the development of hereditary cancers.

PHARMACOGENOMIC/GENETIC TESTING (PGx)

▪Did you know?

▪The food and Drug Administration estimates that 1.3 million people are injured by medication errors annually in the U.S. alone.

▪Until recently, drugs have been developed with the idea that each drug works pretty much the same in everybody. But genomic research has changed that “one size fits all” approach and opened the door to more personalized approaches to using and developing drugs

▪Depending on your genetic makeup, some drugs may work more or less effectively for you than they do in other people. Likewise, some drugs may produce more or fewer side effects in you than in someone else.

▪Pharmacogenomics may also help to save you time and money. By using information about your genetic makeup, doctors may be able to avoid the trial-and-error approach of giving you various drugs that are not likely to work for you until they find the right one. Using pharmacogenomics, the “best-fit” drug to help you can be chosen from the beginning.

▪The U.S. Food and Drug Administration (FDA) also recommends genetic testing before giving the chemotherapy drug mercaptopurine (Purinethol) to patients with acute lymphoblastic leukemia. Some people have a genetic variant that interferes with their ability to process the drug. This processing problem can cause severe side effects and increase risk of infection, unless the standard dose is adjusted according to the patient’s genetic makeup.

▪The FDA also advises doctors to test colon cancer patients for certain genetic variants before administering irinotecan (Camptosar), which is part of a combination chemotherapy regimen. The reasoning is that patients with one particular variant may not be able to clear the drug from their bodies as quickly as others, resulting in severe diarrhea and increased infection risk. Such patients may need to receive lower doses of the drug.

What is Pharmacogenomic/genetic testing?

Pharmacogenetic Testing provides insight into a patient’s genetic propensity to experience a drug-to-drug interaction or to be non-responsive with certain medication classes. This information is invaluable to clinicians whether they are initiating therapy or evaluating a patient’s progress. We evaluate 22 separate genes and over 75 variants to create an easy to understand report that will guide the clinician’s choices in pharmacotherapy.

Pharmacogenomics is the study of how genes affect a person’s response to drugs. With a simple noninvasive cheek swab we are able to help medical professionals and their patients come up with a drug regimen that will specifically work for them based on their genetic makeup. A blueprint that will show how each individual patient will metabolize the drugs they are prescribed. Having this test performed will help a doctor prescribe the right drug, at the right dose, the very first time. It is our mission to drastically reduce the number of adverse drug reactions that happen every single day.

Key Contacts

▪Accounts Payable

Crystal@optimuscommercegroup.com

▪Onboarding

Onboarding@optimuscommercegroup.com

▪Swab orders and general program inquiries

mel@optimuscommercegroup.com

FAQ’s

▪What Insurance Is Accepted?

  •  Medicare Part B
  • Medicaid – Colorado – BRCA requires prior auth, Georgia, Kansas, Kentucky, Missouri, Montana, New Mexico, Ohio, South Carolina, Texas (CGx Only)
  • PPOs accepted – Aetna, Humana, United Health Care, Blue Cross Blue Shield (Anthem) of Florida
  • NO HMO or POS Plans accepted

▪How do I get HIPAA certified?

▪How long does it take for patients to get their results?

  • 4-6 weeks from the date the lab completes the test.

▪What rules and regulations must I be familiar and compliant with?

▪What supplies are available?

  • Orders for mouth swabs can be sent to mel@optimuscommercegroup.com
  • Other supplies like tables, table cloths, scrubs, etc are the responsibility of the IBO.